Martina Kosikova1, Lei Li2, Peter Radvak1, Zhiping Ye1, Xiu-Feng Wan2, Hang Xie1. 1. Laboratory of Pediatric and Respiratory Viral Diseases, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland. 2. Department of Basic Sciences, College of Veterinary Medicine, Mississippi State University.
Abstract
Background: Reduced seasonal influenza vaccine effectiveness (VE) was observed in individuals who received repeated annual vaccinations. Preexisting influenza antibody levels were also found inversely correlated with postvaccination titers. These reports suggest that preexisting immunity may affect contemporary seasonal vaccine performance. Methods: Influenza A/H3 specific cross-reactivity of postvaccination sera from humans with or without preexisting immunity was assessed by hemagglutination inhibition (HAI) assay. Ferret antisera induced by repeated H3 exposures were also subjected to HAI, antibody affinity, and antibody avidity analyses. Results: Human postvaccination sera derived from subjects with or without preexisting immunity showed different cross-reactivity against H3 variant viruses. Similarly, the breadth of cross-reactive ferret antibodies induced by repeated H3 exposures was also broadened. Antigenic differences between H3 viruses characterized by ferret antisera became smaller as the number of exposures increased. Although repeated H3 exposures induced "original antigenic sin" phenomena in HAI titers against later exposed viruses, resultant ferret antibodies showed gradually enhanced avidity for different H3/hemagglutinin. Increased antibody avidity was found to be inversely correlated with decreased antigenic differences among H3 viruses characterized. Conclusions: Our results suggest that repeated H3 exposures imprinted not only antibody quantity but also antibody quality. The "naive" ferret model currently used for vaccine strain selection does not recapitulate the complexity of human preexisting immunity. Vaccine strains identified hereby may not provide coverage sufficient for those who were frequently infected and/or vaccinated, leading to the reduced VE observed.
Background: Reduced seasonal influenza vaccine effectiveness (VE) was observed in individuals who received repeated annual vaccinations. Preexisting influenza antibody levels were also found inversely correlated with postvaccination titers. These reports suggest that preexisting immunity may affect contemporary seasonal vaccine performance. Methods: Influenza A/H3 specific cross-reactivity of postvaccination sera from humans with or without preexisting immunity was assessed by hemagglutination inhibition (HAI) assay. Ferret antisera induced by repeated H3 exposures were also subjected to HAI, antibody affinity, and antibody avidity analyses. Results:Human postvaccination sera derived from subjects with or without preexisting immunity showed different cross-reactivity against H3 variant viruses. Similarly, the breadth of cross-reactive ferret antibodies induced by repeated H3 exposures was also broadened. Antigenic differences between H3 viruses characterized by ferret antisera became smaller as the number of exposures increased. Although repeated H3 exposures induced "original antigenic sin" phenomena in HAI titers against later exposed viruses, resultant ferret antibodies showed gradually enhanced avidity for different H3/hemagglutinin. Increased antibody avidity was found to be inversely correlated with decreased antigenic differences among H3 viruses characterized. Conclusions: Our results suggest that repeated H3 exposures imprinted not only antibody quantity but also antibody quality. The "naive" ferret model currently used for vaccine strain selection does not recapitulate the complexity of human preexisting immunity. Vaccine strains identified hereby may not provide coverage sufficient for those who were frequently infected and/or vaccinated, leading to the reduced VE observed.
Authors: Jill M Ferdinands; Alicia M Fry; Sue Reynolds; Joshua Petrie; Brendan Flannery; Michael L Jackson; Edward A Belongia Journal: Clin Infect Dis Date: 2016-12-29 Impact factor: 9.079
Authors: Jiwon Lee; Daniel R Boutz; Veronika Chromikova; M Gordon Joyce; Christopher Vollmers; Kwanyee Leung; Andrew P Horton; Brandon J DeKosky; Chang-Han Lee; Jason J Lavinder; Ellen M Murrin; Constantine Chrysostomou; Kam Hon Hoi; Yaroslav Tsybovsky; Paul V Thomas; Aliaksandr Druz; Baoshan Zhang; Yi Zhang; Lingshu Wang; Wing-Pui Kong; Daechan Park; Lyubov I Popova; Cornelia L Dekker; Mark M Davis; Chalise E Carter; Ted M Ross; Andrew D Ellington; Patrick C Wilson; Edward M Marcotte; John R Mascola; Gregory C Ippolito; Florian Krammer; Stephen R Quake; Peter D Kwong; George Georgiou Journal: Nat Med Date: 2016-11-07 Impact factor: 53.440
Authors: Colin A Russell; Terry C Jones; Ian G Barr; Nancy J Cox; Rebecca J Garten; Vicky Gregory; Ian D Gust; Alan W Hampson; Alan J Hay; Aeron C Hurt; Jan C de Jong; Anne Kelso; Alexander I Klimov; Tsutomu Kageyama; Naomi Komadina; Alan S Lapedes; Yi P Lin; Ana Mosterin; Masatsugu Obuchi; Takato Odagiri; Albert D M E Osterhaus; Guus F Rimmelzwaan; Michael W Shaw; Eugene Skepner; Klaus Stohr; Masato Tashiro; Ron A M Fouchier; Derek J Smith Journal: Vaccine Date: 2008-09-12 Impact factor: 3.641
Authors: Min Z Levine; Judith M Martin; F Liaini Gross; Stacie Jefferson; Kelly Stefano Cole; Crystal Ann Archibald; Mary Patricia Nowalk; Michael Susick; Krissy Moehling; Sarah Spencer; Jessie R Chung; Brendan Flannery; Richard K Zimmerman Journal: Clin Vaccine Immunol Date: 2016-10-04
Authors: Guozhang Zou; Martina Kosikova; Su-Ryun Kim; Shweta Kotian; Wells W Wu; Rongfong Shen; David N Powers; Cyrus Agarabi; Hang Xie; Tongzhong Ju Journal: J Biol Chem Date: 2018-10-12 Impact factor: 5.157
Authors: Lei Li; Siriruk Changrob; Yanbin Fu; Olivia Stovicek; Jenna J Guthmiller; Joshua J C McGrath; Haley L Dugan; Christopher T Stamper; Nai-Ying Zheng; Min Huang; Patrick C Wilson Journal: Brief Bioinform Date: 2022-03-10 Impact factor: 13.994
Authors: Maria Auladell; Xiaoxiao Jia; Luca Hensen; Brendon Chua; Annette Fox; Thi H O Nguyen; Peter C Doherty; Katherine Kedzierska Journal: Front Immunol Date: 2019-07-02 Impact factor: 7.561